Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 12,739 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Male Clear all
Active, not recruiting Phase 1 Interventional

Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

NCT02808208
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Vascular Access Complication
Interventions
Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC), Placebo, Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 3 Interventional

Treatment of Panic Disorder: Long Term Strategies

NCT00000368
View directory record Official record
Conditions
Panic Disorder, Agoraphobia
Interventions
Cognitive behavior therapy, Paroxetine or other medication - algorithm used
Behavioral · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
4
States / cities
New Haven, Connecticut • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 25, 2026, 2:58 PM EDT
Terminated Phase 2 Interventional

Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

NCT00323791
View directory record Official record
Conditions
Kidney Cancer
Interventions
gemcitabine hydrochloride, imatinib mesylate, gene expression analysis, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Nuun SPORT on Subjective Exercise Performance in Male and Female Runners

NCT05510791
View directory record Official record
Conditions
Hydration
Interventions
Nuun Sport Drink, Control
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer

NCT02885974
View directory record Official record
Conditions
Bladder Cancer
Interventions
Celecoxib, Gemcitabine, Cisplatin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence of Two Transdermal Clonidine Administrations in Healthy Volunteers

NCT02096744
View directory record Official record
Conditions
Healthy
Interventions
Catapres-TTS-1, Intervention 1: Catapres-TTS-3, Intervention 2: Catapres-TTS-3
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Oct 25, 2026, 2:58 PM EDT
Terminated Phase 2 Interventional Results available

Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors

NCT01808534
View directory record Official record
Conditions
Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Malignant Extragonadal Germ Cell Tumor, Malignant Extragonadal Non-Seminomatous Germ Cell Tumor, Extragonadal Seminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Ovarian Germ Cell Tumor
Interventions
palifosfamide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Indianapolis, Indiana • Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Oct 25, 2026, 2:58 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Chronic Radiation Cystitis and Effect of Hyperbaric Oxygen Therapy on Patient Reported Outcomes and Urine Inflammatory Biomarkers

NCT07368647
View directory record Official record
Conditions
Radiation Cystitis, Urinary Tract Infection (Diagnosis)
Interventions
Hyperbaric Oxygen Therapy
Other
Lead sponsor
Rachel A. Moses
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer

NCT00374049
View directory record Official record
Conditions
Prostate Cancer
Interventions
MUC_1
Drug
Lead sponsor
Olivera Finn
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)

NCT03230838
View directory record Official record
Conditions
Complicated Urinary Tract Infection, Pyelonephritis
Interventions
Ceftolozane/Tazobactam, Meropenem
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
7 Days to 17 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Not applicable Interventional

Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting

NCT01440855
View directory record Official record
Conditions
Prostate Cancer, Breast Cancer, Colorectal Cancer, Thoracic Cancer
Interventions
CIS (Cancer Information Service) Information Sheet, Facing Forward booklet
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Oct 25, 2026, 2:58 PM EDT
Not yet recruiting Phase 3 Interventional

Effectiveness of Medical and Environmental Interventions to Reduce Cystoscopy Discomfort (CystoDiscomfort)

NCT07795255
View directory record Official record
Conditions
Bladder (Urothelial, Transitional Cell) Cancer, Hematuria
Interventions
Headphones, Dwell time 5-10 minutes, Dwell Time more than 10 minutes
Device · Drug
Lead sponsor
Florian Schroeck
Federal
Eligibility
18 Years and older
Enrollment
1,740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina • Wilmington, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Not applicable Interventional Results available

Care Coordination/Home Telehealth to Safeguard Care in CKD

NCT03038126
View directory record Official record
Conditions
Safety Issues, Chronic Kidney Disease
Interventions
CCHT, Usual care
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
60 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

NCT04704219
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Pembrolizumab, Lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Billings, Montana • Las Vegas, Nevada + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 25, 2026, 2:58 PM EDT
Recruiting Not applicable Interventional

Poly-L-Lactic Acid for Vulvovaginal Tissue Regeneration

NCT07544667
View directory record Official record
Conditions
Pelvic Organ Prolapse (POP), Cystocele, Pelvic Floor Disorder
Interventions
Poly-L-Lactic Acid (Sculptra) injection, Placebo injection (sterile water)
Device · Other
Lead sponsor
Cassandra Kisby
Other
Eligibility
21 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 25, 2026, 2:58 PM EDT
Recruiting No phase listed Observational

MRI/Ultrasound Fusion Guided Laser Ablation of Prostate Cancer

NCT05241236
View directory record Official record
Conditions
Neoplasms Prostate, Cancer of the Prostate
Interventions
Image Fusion (MR/US) Software Registration Guided Laser Ablation of Prostate Cancer
Device
Lead sponsor
Urological Research Network, LLC
Other
Eligibility
50 Years and older · Male only
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2038
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer

NCT02217709
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
phenelzine sulfate, laboratory biomarker analysis, questionnaire administration
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
Beverly Hills, California • Los Angeles, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 25, 2026, 2:58 PM EDT
Recruiting No phase listed Observational

Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires

NCT05567198
View directory record Official record
Conditions
Systemic Lupus Erythematosus (Sle), Primary Ovarian Insufficiency (Poi)
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 120 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 2:58 PM EDT
Recruiting Not applicable Interventional

EPPIC: Easing Pelvic Pain Interventions Clinical Research Program

NCT05127616
View directory record Official record
Conditions
Urologic Chronic Pelvic Pain Syndrome (UCPPS), Interstitial Cystitis, Bladder Pain Syndrome, Chronic Prostatitis, Chronic Pain, Chronic Pelvic Pain Syndrome, Chronic Overlapping Pain Disorders
Interventions
Minimal Contact-Cognitive Behavior Therapy, Patient Education/Support
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Function

NCT02436447
View directory record Official record
Conditions
Normal and Impaired Renal Function
Interventions
MTP-131
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Maimi, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 25, 2026, 2:58 PM EDT
Completed No phase listed Observational

A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).

NCT05858749
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 25, 2026, 2:58 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

NCT06053658
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Tivozanib, Nivolumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Irvine, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 25, 2026, 2:58 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus

NCT03052400
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Insulin Resistance
Interventions
Mifepristone 600 mg daily, Placebo
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Oct 25, 2026, 2:58 PM EDT
Completed Not applicable Interventional Results available

Achieving Medication Safety During Acute Kidney Injury

NCT01134900
View directory record Official record
Conditions
Kidney Failure, Acute
Interventions
Pharmacy Dashboard Review and Intervention
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Oct 25, 2026, 2:58 PM EDT